Product Details
| Product Name:
lorvotuzumab |
CAS No.:
339306-30-8 |
| Purity:
> 95% |
Supply Ability:
10g |
| Release date:
2024/11/15 |
Product Introduction
Bioactivity
| 名称 | lorvotuzumab |
| 描述 | Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine. |
| 体内活性 | Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate (ADC) that utilizes a disulfide linker to connect the potent anti-mitotic agent DM1 to the CD56-targeting antibody (Lorvotuzumab). Lorvotuzumab mertansine is effective against Wilms' tumor, rhabdomyosarcoma, and neuroblastoma. |
| 存储条件 | store at low temperature | store at -80°C | Shipping with blue ice. |
| 相关产品 | Belantamab | Naratuximab | Trastuzumab | Daratumumab | Datopotamab | Enfortumab | Inebilizumab | Lonigutamab | Polatuzumab | Sacituzumab | Disitamab | Glembatumumab |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:704878-75-1
$289.00 / 1mg
-
CAS:105099-89-6
$98.00 / 5mg
-
CAS:78415-72-2
$36.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States